Treatment options after sorafenib failure in patients with hepatocellular carcinoma
Explore this paper's citation graph
Summary
The most relevant to date published literature on treatment options beyond sorafenib, reported studies, ongoing investigational efforts, and possibilities for future studies in advanced hepatocellular carcinoma are reviewed.
- Type
- review
- Published
- 2017-11-20
- Cited by
- 37
- References
- 52
- Access
- Open access
- OpenAlex
- https://openalex.org/W2769323635
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:9400799
Keywords
Sorafenib, Hepatocellular carcinoma, Medicine, Internal medicine, Oncology
References
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
- Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
- Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein
- Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
- Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial
- Modes of resistance to anti-angiogenic therapy
- A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
- HCC and angiogenesis: possible targets and future directions
- Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
- Angiogenesis Soluble Factors as Hepatocellular Carcinoma Noninvasive Markers for Monitoring Hepatitis C Virus Cirrhotic Patients Awaiting Liver Transplantation
- Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
- Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.
- Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
- Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.
- Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study
- Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
- Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma
Cited by
- Novel Albumin–Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization
- LncRNA NR2F1‐AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR‐363
- Why develop photoactivated chemotherapy?
- Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience
- Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications
- Control of intracranial disease is associated with improved survival in patients with brain metastasis from hepatocellular carcinoma
- Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
- Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
- Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells
- Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma
- Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients
- EpCAM-high liver cancer stem cells resist natural killer cell–mediated cytotoxicity by upregulating CEACAM1
- Formulation, Preparation and Evaluation of Nanostructured Lipid Carrier Containing Naringin and Coix Seed Oil for Anti-Tumor Application Based on “Unification of Medicines and Excipients”
- Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
- Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma
- Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma
- Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma
- Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells
- Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea
- LncRNA PCGEM1 mediates oxaliplatin resistance in hepatocellular carcinoma via miR-129-5p/ETV1 axis in vitro.
Related papers
- Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
- Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma
- High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma
- Heat Shock Protein 27 Expression Levels are associated with the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib
- Sorafenib in hepatocellular carcinoma.
- Data from High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma
- Supplementary Methods from SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Anti–Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model
- Complete Regression of Recurrent Advanced Hepatocellular Carcinoma After Liver Transplantation in Response to Sorafenib Treatment: A Case Report.